CYBX 54.98 Cyberonics Inc $CYBX Hit a 52 week low of 48.19

New Post Public Reply Private Reply Replies (0) Message Board

Nov 20, 2014 at 11:16 AM

CYBX 54.98 Cyberonics Inc $CYBX Hit a 52 week low of 48.19 Closing the day 10:45 at 54.98 +6.47 +13.34% With a day low of 48.19 and a total volume of 494,947.

CYBX Recent Posts: http://investorshangout.com/Cyberonics-Inc-CYBX-53862/

CYBX Cyberonics Inc Recent Headline News

Cyberonics up after FQ2 report
Seeking Alpha - at Seeking Alpha - 54 mins ago

CYBX: 54.36 (+5.85)

Cyberonics (CYBX) Marked As A Barbarian At The Gate
at The Street - 58 mins ago
Trade-Ideas LLC identified Cyberonics (CYBX) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
CYBX: 54.36 (+5.85)

Cyberonics (CYBX) Q2 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - 2 hrs 20 mins ago

CYBX: 54.36 (+5.85)

Cyberonix updates guidance after FQ2 results
Seeking Alpha - at Seeking Alpha - 2 hrs 22 mins ago

CYBX: 54.36 (+5.85)

Cyberonics beats 2Q profit forecasts
Automated Insights - Thu Nov 20, 6:18AM CST
HOUSTON (AP) _ Cyberonics Inc. (CYBX) on Thursday reported earnings of $17.3 million in its fiscal second quarter.
CYBX: 54.36 (+5.85)

Cyberonics beats by $0.05, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 6:05AM CST

CYBX: 54.36 (+5.85)

Cyberonics Reports Fiscal 2015 Second Quarter Results
PR Newswire - Thu Nov 20, 6:00AM CST
Cyberonics, Inc. (NASDAQ:CYBX) today announced results for the quarter ended October 24, 2014.
CYBX: 54.36 (+5.85)

Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 4:30PM CST

GLOG: 18.88 (+0.22), LQDT: 10.34 (-1.16), PDCO: 47.07 (+0.72), BBY: 38.14 (+2.60), SPB: 89.90 (-1.50), DCI: 40.00 (-2.75), WBAI: 23.86 (-0.54), CYBX: 54.36 (+5.85), JKS: 22.72 (-0.81), PERY: 23.91 (-0.05), DLTR: 65.70 (+3.07), BONT: 8.87 (-0.03), PLCE: 52.42 (+1.05), DATE: 5.10 (-0.19), MBLY: 45.37 (-1.38), BKE: 50.78 (+1.32), BRC: 23.26 (-0.24), SMRT: 14.10 (+0.75)

Epilepsy Patients And Advocates Urged To Deck Their Halls With Purple Lights This Holiday Season
PR Newswire - Wed Nov 19, 10:13AM CST
As the holiday season approaches and people begin planning their decorations, Cyberonics, Inc. is urging them to maintain the momentum of Epilepsy Awareness Month in November by incorporating purple lights into their holiday decor.
CYBX: 54.36 (+5.85)

Only one week left to register for the free Houston area Veteran and Transitioning Military Career Event hosted by Cyberonics
PR Newswire - Thu Nov 13, 7:00AM CST
On November 19th 2014, Houston TX based Cyberonics (www.cyberonics.com) will partner with the MedTech and BioTech Veterans Program (www.mvpvets.org) to conduct a re-careering event for transitioning military and veterans in the Houston, Texas area. There are still seats remaining for this free and innovative opportunity for veterans and transitioning military personnel to learn more about employment opportunities at Cyberonics and in the Medical Device Manufacturing industry.
CYBX: 54.36 (+5.85)

Neurostimulation Devices Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Competitive Scenario And Forecasts, 2012 To 2020
M2 - Thu Nov 13, 2:52AM CST
Industry Insights
BSX: 13.03 (-0.06), MDT: 71.47 (-0.29), CYBX: 54.36 (+5.85)

Cyberonics Shares Down 12.7% Since SmarTrend's Sell Call (CYBX)
Comtex SmarTrend(R) - Mon Nov 10, 9:58AM CST
SmarTrend identified a Downtrend for Cyberonics (NASDAQ:CYBX) on August 22nd, 2014 at $57.31. In approximately 3 months, Cyberonics has returned 12.71% as of today's recent price of $50.02.
CYBX: 54.36 (+5.85)

Seats remaining for the Houston area MVP and Cyberonics Veteran and Transitioning Military Re-careering Event
PR Newswire - Mon Nov 10, 7:00AM CST
On November 19th, 2014, Houston, TX based Cyberonics (www.cyberonics.com) will partner with the MedTech and BioTech Veterans Program (www.mvpvets.org) to conduct a re-careering event for transitioning military and veterans in the Houston, Texas area. There are still seats remaining for this free and innovative opportunity for veterans and transitioning military personnel to learn more about employment opportunities at Cyberonics and in the Medical Device Manufacturing industry.
CYBX: 54.36 (+5.85)

Cyberonics To Report Fiscal Year 2015 Second Quarter Results And Host Webcast And Conference Call On November 20, 2014
PR Newswire - Thu Nov 06, 8:00AM CST
Cyberonics, Inc. (NASDAQ:CYBX) today announced that the company will report financial results for the second quarter ended October 24, 2014 on Thursday, November 20, 2014 before regular market trading hours. The company will conduct a conference call to discuss those results on the same day at 8:00 AM Central Time (9:00 AM Eastern Time).
CYBX: 54.36 (+5.85)

10.4% Return Seen to Date on SmarTrend Cyberonics Call (CYBX)
Comtex SmarTrend(R) - Mon Oct 27, 11:10AM CDT
SmarTrend identified a Downtrend for Cyberonics (NASDAQ:CYBX) on August 22nd, 2014 at $57.31. In approximately 2 months, Cyberonics has returned 10.44% as of today's recent price of $51.32.
CYBX: 54.37 (+5.86)

MedTech and BioTech Veterans Program and Cyberonics Announce Veteran and Transitioning Military Re-careering Event
PR Newswire - Tue Oct 14, 7:00AM CDT
On November 19, 2014, Houston, TX-based Cyberonics, Inc. (NASDAQ: CYBX; www.cyberonics.com) will partner with the MedTech and BioTech Veterans Program (www.mvpvets.org) to conduct a re-careering event for transitioning military and veterans in south Texas.
CYBX: 54.37 (+5.86)

Downtrend Call Working As Cyberonics Stock Falls 12.4% (CYBX)
Comtex SmarTrend(R) - Thu Oct 02, 10:05AM CDT
SmarTrend identified a Downtrend for Cyberonics (NASDAQ:CYBX) on August 22nd, 2014 at $57.31. In approximately 1 month, Cyberonics has returned 12.38% as of today's recent price of $50.21.
CYBX: 54.37 (+5.86)

Interesting CYBX Put And Call Options For November 22nd
DividendChannel.com - Tue Sep 30, 10:03AM CDT
Investors in Cyberonics, Inc. saw new options begin trading this week, for the November 22nd expiration.
CYBX: 54.37 (+5.86)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hims & Hers Faces FTC Heat: Investor Class Action Looms

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

China's 15th Plan: Key Moves in the Capital Markets

Riding the Waves of Reform in China The winds of change are blowing through China's capital markets, and Guosen Securities is putting a stake in the ground with bold priorities for the 15th Five-Year Plan. As far as I'm concerned, the headlines here are thick with implications for anyone eyeing a piece of China's economic pie from 2026–2030. The Pillars of Stability and...

CStone's CS2009: A Leap in Cancer Treatment Validated

CStone's Game-Changer: CS2009 in the Spotlight CStone Pharmaceuticals just pulled a rabbit out of a hat at the ESMO 2026 Congress, showcasing the clinical might of their CS2009. This ain't just another hype train, folks. We're talking about a trispecific antibody targeting PD-1, VEGF, and CTLA-4. With data rolled out from over 300 patients, this compound promises a...

NOTHING NINE's Global Ambitions: Paris Show's Impact

Paris: Stage or Launchpad? You’d think walking that catwalk in Paris is the holy grail—fashion's own illustrious red carpet. But when you're Chloe, founder of NOTHING NINE, the real hustle kicks off once the lights dim. On 29th September 2026, this designer brand strutted its stuff at one of the grandest venues, Les Invalides, part of the prestigious Paris Fashion...

Ambient AI Shows Promise for Boosting Cancer Care Efficiency

Study Points to Ambient AI's Promise in Oncology Some days, the world of cancer care is a real beast to tackle. But today, we've got a glimpse into how technology, and specifically ambient AI, might just help slay some of the burdens that these healthcare warriors face daily. The Florida Cancer Specialists & Research Institute (FCS) joined hands to dive into how this tech...

Superteam Wheels Rides Into Spain with RACEIT Deal

Rolling Out the Red Carpet for Spanish Cyclists Think of it as the pedal-powered bridge from wherever Superteam Wheels calls home to the sunny streets of Spain. If you're in the cycling game, this new partnership between Superteam Wheels and COMERTECH RACEIT, S.L., better known as RACEIT, is drawing a line in the sand—or perhaps on the asphalt—across Europe. Starting...

Zinzino Eyes European Market With New Botanical Line

Zinzino's Strategic Play in Europe's Wellness Market There's a new player on the European wellness block, and it's Zinzino's latest concoction of fermented botanical supplements. This isn't just your run-of-the-mill vitamin shop stock; we're talking about a lineup crafted for distinct parts of the day, reflecting an evolving consumer trend. People are looking for tailored...

HCLTech Partners with Rapidus on Semiconductor Future

Making Sense of the HCLTech and Rapidus Collaboration When you're talking about the world of semiconductors, no two words get tossed around more than innovation and speed. Now, with the recent partnership between HCLTech and Rapidus, those words are bound to echo from India to Japan and beyond. We have HCLTech, a stalwart of global technology, teaming up with Rapidus, a...

ASICS and University of Michigan Launch Innovation Lab

Running Innovation Gets a Boost in Ann Arbor On a crisp fall day up in Ann Arbor, ASICS and the University of Michigan have decided it's high time to shake up the world of running product R&D. These two powerhouses just launched the ASICSx Michigan Sport Innovation Center (AMSI), an academic-industry research lab. It's like they're mixing college smarts with business...

Ivonescimab Promises New Hope for Advanced BTC Patients

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...